Hyllengren Eric J — SEC Form 4 filings
SEC reporting owner CIK 1966926. 11 Form 4 filings on record with FilingPulse; latest filed 2026-07-14.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-01-09 to 2026-07-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 5 filings — 38,972 shares, $53,327 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 28,648 shares @ $0.62 ($17,676) in Atara Biotherapeutics, Inc., filed 2024-05-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | — | 8 | — | 7 legs · 38,972 sh · $53,327 | 12 |
| Zura Bio Ltd (ZURA) | Chief Financial Officer | 2 | — | — | 2 |
| Tenaya Therapeutics, Inc. (TNYA) | Chief Financial Officer | 1 | — | — | 1 |
Form 4 filings — Hyllengren Eric J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-14 | 4 | Tenaya Therapeutics, Inc. (TNYA) | Grant/award (A): 1,650,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Zura Bio Ltd (ZURA) | Grant/award (A): 340,900 (derivative) @ $0 | EDGAR |
| 2025-07-17 | 4 | Zura Bio Ltd (ZURA) | Grant/award (A): 672,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Disposition to issuer (D): 1,900 (derivative) @ $0 · Disposition to issuer (D): 460 (derivative) @ $0 · Disposition to issuer (D): 496 (derivative) @ $0 · Disposition to issuer (D): 154 (derivative) @ $0 · Disposition to issuer (D): 381 (derivative) @ $0 · Disposition to issuer (D): 350 (derivative) @ $0 · +4 more | EDGAR |
| 2025-03-05 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,211 @ $7.00 | EDGAR |
| 2025-01-29 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 34,050 @ $0 | EDGAR |
| 2024-11-20 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,364 @ $11.20 | EDGAR |
| 2024-08-20 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,041 @ $6.63 · Sale (S): 29 @ $6.63 | EDGAR |
| 2024-05-20 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 28,648 @ $0.62 | EDGAR |
| 2024-03-06 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,462 @ $0.72 · Sale (S): 5,217 @ $0.72 | EDGAR |
| 2024-01-09 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 475,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1966926 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →